New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 27, 2014
07:21 EDTMRK, BAXMerck names Robert Davis as CFO, effective April 23
Merck (MRK) announced the appointment of Robert M. Davis as executive vice president and CFO, effective April 23, 2014. Davis, who will also oversee corporate strategy and corporate business development, will succeed Peter N. Kellogg. Kellogg will work closely with Davis to ensure a seamless transition and will leave Merck on May 16. Davis is corporate vice president and president of Baxter’s (BAX) Medical Products business.
News For MRK;BAX From The Last 14 Days
Check below for free stories on MRK;BAX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 31, 2014
12:39 EDTBAXFDA panel says HyQvia has favorable benefit-risk ratio, Bloomberg reports
Subscribe for More Information
09:54 EDTMRKSunTrust recommends swapping into Merck and out of Pfizer
SunTrust recommends swapping into Merck (MRK) and out of Pfizer (PFE). The firm sees more upside to Merck's numbers and notes Pfize has lost a considerable amount of exclusivity and pipeline contribution will not be enough to make up the difference.
07:10 EDTBAXFDA Blood Products Advisory Committee to hold a meeting
Subscribe for More Information
07:06 EDTMRKColumbia Laboratories CEO sees Q3 revenues improving
Columbia Laboratories (CBRX) CEO stated, "The routine license renewal by Merck (MRK) Serono for one of its high-volume, high-margin markets is expected to be complete in 2H14, whereupon normal shipments will then resume at the beginning of 2015. The new license will be in place for five years, thereby restoring the predictability of this long-term revenue stream. In the interim, Merck Serono placed an order with us as part of a one-time exception during the renewal process. The order will be shipped in Q3 and benefit that quarter's revenues. In terms of the services business, we expect a sequential improvement in Q3 revenues due to successful recent business development activities and customer interest in our comprehensive suite of advanced technologies."
July 30, 2014
08:08 EDTBAXBaxter announces divestiture of commercial vaccines business to Pfizer for $635M
Baxter International (BAX) announced that it has entered into a definitive agreement to sell its two commercially marketed vaccines and related production facilities to Pfizer (PFE) for a total cash consideration of $635M, subject to certain adjustments. The sale includes the company’s commercial vaccines business, which is comprised of NeisVac-C, a vaccine which helps protect against meningitis caused by group C meningococcal meningitis, and FSME-IMMUN, which helps protect against tick-borne encephalitis, an infection of the brain transmitted by the bite of ticks infected with the TBE-virus. Both vaccines are currently available outside the United States, primarily in a number of European markets. Baxter continues to explore strategic options, including the potential for partnering or divesting its R&D development programs focused on influenza and Lyme disease. Subject to regulatory approvals and other customary closing conditions, the companies expect to close the transaction by the end of 2014. Baxter expects 2014 vaccines revenues to total approximately $300M and adjusted earnings of approximately 25c per diluted share, including approximately $50M of one-time milestone payments related to the ongoing government collaborations for development of influenza vaccines. Baxter expects the transaction to be modestly dilutive to fourth quarter 2014 adjusted earnings and dilutive to 2015 adjusted earnings by approximately 15c per diluted share.
08:01 EDTBAXPfizer enters into agreement to acquire Baxter's portfolio of marketed vaccines
Subscribe for More Information
July 29, 2014
12:13 EDTMRKOn The Fly: Midday Wrap
Subscribe for More Information
09:44 EDTMRKMerck CEO says has not been urged for big consolidation deal, CNBC says
Subscribe for More Information
08:32 EDTMRKMerck says not interested in deal solely, primarily for inversion
Subscribe for More Information
07:19 EDTMRKCBI to hold a conference
Subscribe for More Information
06:59 EDTMRKMerck sees FY14 revenue $42.4B-$43.2B, consensus $42.56B
Subscribe for More Information
06:58 EDTMRKMerck reports Q2 Januvia sales $1.58B, Q2 Zetia sales $1.13B
Reports Q2 Remicade sales $607M; Q2 Isentress sales $453M; Q2 Gardasili sales $409M; Q2 Proquad sales $326M; Q2 Singulair sales $284M; Q2 Nanosex sales $258M.
06:57 EDTMRKMerck sees FY14 non-GAAP EPS $3.43-$3.53, consensus $3.48
Subscribe for More Information
06:57 EDTMRKMerck reports Q2 non-GAAP EPS 85c, consensus 81c
Subscribe for More Information
July 28, 2014
15:47 EDTMRKNotable companies reporting before tomorrow's open
Subscribe for More Information
14:03 EDTMRKEarnings Preview: Merck's pharmaceutical sales dependent on newer drugs
Subscribe for More Information
10:36 EDTMRKMerck August weekly volatility elevated into Q2 and outlook
Merck August weekly call option implied volatility is at 26, August is at 16, September is at 15, January is at 16; compared to its 26-week average of 18 according to Track Data, suggesting large near term price movement into the expected release of Q2 result on July 29.
July 24, 2014
08:32 EDTMRKMerck initiates Phase 3 study of Letermovir
Subscribe for More Information
July 21, 2014
07:21 EDTMRKGilead could be hurt by new HCV drugs, says Wells Fargo
Noting that data on a new Merck (MRK) HCV treatment is expected in November, Wells Fargo thinks Merck's HCV drug could be combined with Gilead's (GILD) Sovaldi to shorten the duration of treatment to four weeks. Other companies could take similar actions, and Gilead's per patient revenues would be significantly reduced if this occurs, the firm warned. However, it continues to have an upbeat outlook on Gilead heading into what it sees as a strong quarter and is still upbeat on the company's long-term HCV opportunity. It keeps an Outperform rating on Gilead.
06:43 EDTMRKGrowing market for hepatitis-C treatment prompts legal scramble, WSJ says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use